CN106822027A - 一种欧米加‑3酸及其衍生物肠溶软胶囊及其制备方法 - Google Patents
一种欧米加‑3酸及其衍生物肠溶软胶囊及其制备方法 Download PDFInfo
- Publication number
- CN106822027A CN106822027A CN201710073553.3A CN201710073553A CN106822027A CN 106822027 A CN106822027 A CN 106822027A CN 201710073553 A CN201710073553 A CN 201710073553A CN 106822027 A CN106822027 A CN 106822027A
- Authority
- CN
- China
- Prior art keywords
- enteric
- soft capsules
- acid
- derivative
- omega
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 107
- 239000002253 acid Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 title abstract 14
- 235000020661 alpha-linolenic acid Nutrition 0.000 title abstract 7
- 229960004488 linolenic acid Drugs 0.000 title abstract 7
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 26
- 239000003549 soybean oil Substances 0.000 claims abstract description 26
- 239000002702 enteric coating Substances 0.000 claims abstract description 24
- 238000009505 enteric coating Methods 0.000 claims abstract description 24
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000012530 fluid Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000003463 adsorbent Substances 0.000 claims abstract description 6
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 6
- 239000000375 suspending agent Substances 0.000 claims abstract description 6
- 239000004014 plasticizer Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims description 44
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 34
- 239000003292 glue Substances 0.000 claims description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 238000000576 coating method Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- 239000011248 coating agent Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229940087168 alpha tocopherol Drugs 0.000 claims description 17
- 229920000159 gelatin Polymers 0.000 claims description 17
- 239000008273 gelatin Substances 0.000 claims description 17
- 229960000984 tocofersolan Drugs 0.000 claims description 17
- 239000002076 α-tocopherol Substances 0.000 claims description 17
- 235000004835 α-tocopherol Nutrition 0.000 claims description 17
- 108010010803 Gelatin Proteins 0.000 claims description 15
- 235000019322 gelatine Nutrition 0.000 claims description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 238000010792 warming Methods 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 230000036760 body temperature Effects 0.000 claims description 8
- 238000009833 condensation Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000005096 rolling process Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 11
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 8
- 239000008279 sol Substances 0.000 description 8
- 235000013871 bee wax Nutrition 0.000 description 7
- 239000012166 beeswax Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 6
- 239000000787 lecithin Substances 0.000 description 6
- 235000010445 lecithin Nutrition 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- 239000001069 triethyl citrate Substances 0.000 description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 6
- 235000013769 triethyl citrate Nutrition 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 5
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical group CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- -1 acetate benzenetricarboxylic acid ester Chemical class 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000012461 cellulose resin Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000010647 garlic oil Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008342 pharmaceutical dispersion Substances 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710073553.3A CN106822027B (zh) | 2017-02-10 | 2017-02-10 | 一种欧米加-3酸及其衍生物肠溶软胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710073553.3A CN106822027B (zh) | 2017-02-10 | 2017-02-10 | 一种欧米加-3酸及其衍生物肠溶软胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106822027A true CN106822027A (zh) | 2017-06-13 |
CN106822027B CN106822027B (zh) | 2020-04-03 |
Family
ID=59122268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710073553.3A Active CN106822027B (zh) | 2017-02-10 | 2017-02-10 | 一种欧米加-3酸及其衍生物肠溶软胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106822027B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112315991A (zh) * | 2020-12-10 | 2021-02-05 | 西双版纳华坤生物科技有限责任公司 | 一种血塞通药物组合物及其制备方法及应用 |
CN112352953A (zh) * | 2020-11-17 | 2021-02-12 | 西双版纳华坤生物科技有限责任公司 | 一种预防心脑血管病的组合物及其制备方法和应用 |
CN114711321B (zh) * | 2022-03-19 | 2024-03-15 | 浙江新研坤科技有限公司 | 添加有植物型欧米伽3的南极磷虾油凝胶糖果及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850084A (zh) * | 2006-03-13 | 2006-10-25 | 宛六一 | 一种药物组合物软胶囊及其制备方法 |
CN101049380A (zh) * | 2007-05-11 | 2007-10-10 | 张冰文 | 含有山茶油的肠溶软胶囊及其制备方法 |
CN103908441A (zh) * | 2013-12-26 | 2014-07-09 | 力品药业(厦门)有限公司 | 一种Omega-3脂肪酸及其衍生物肠溶软胶囊及制备方法 |
US20160000740A1 (en) * | 2014-06-26 | 2016-01-07 | Banner Life Sceinces | Enhanced bioavailability of polyunsaturated fatty acids |
CN105997926A (zh) * | 2016-05-18 | 2016-10-12 | 黑龙江大学 | 一种双歧杆菌结肠溶软胶囊及其制备方法 |
-
2017
- 2017-02-10 CN CN201710073553.3A patent/CN106822027B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850084A (zh) * | 2006-03-13 | 2006-10-25 | 宛六一 | 一种药物组合物软胶囊及其制备方法 |
CN101049380A (zh) * | 2007-05-11 | 2007-10-10 | 张冰文 | 含有山茶油的肠溶软胶囊及其制备方法 |
CN103908441A (zh) * | 2013-12-26 | 2014-07-09 | 力品药业(厦门)有限公司 | 一种Omega-3脂肪酸及其衍生物肠溶软胶囊及制备方法 |
US20160000740A1 (en) * | 2014-06-26 | 2016-01-07 | Banner Life Sceinces | Enhanced bioavailability of polyunsaturated fatty acids |
CN105997926A (zh) * | 2016-05-18 | 2016-10-12 | 黑龙江大学 | 一种双歧杆菌结肠溶软胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
杨瑞虹主编: "《药物制剂技术与设备》", 31 August 2010 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112352953A (zh) * | 2020-11-17 | 2021-02-12 | 西双版纳华坤生物科技有限责任公司 | 一种预防心脑血管病的组合物及其制备方法和应用 |
CN112315991A (zh) * | 2020-12-10 | 2021-02-05 | 西双版纳华坤生物科技有限责任公司 | 一种血塞通药物组合物及其制备方法及应用 |
CN114711321B (zh) * | 2022-03-19 | 2024-03-15 | 浙江新研坤科技有限公司 | 添加有植物型欧米伽3的南极磷虾油凝胶糖果及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106822027B (zh) | 2020-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104886554B (zh) | 爆珠软胶囊及其制备方法 | |
CN101045062B (zh) | 多烯磷脂酰胆碱的肠溶制剂及其制备方法和药物应用 | |
CN106176683B (zh) | 一种盐酸曲马多缓释胶囊及其制备方法和用途 | |
CN106822027A (zh) | 一种欧米加‑3酸及其衍生物肠溶软胶囊及其制备方法 | |
CN107072957B (zh) | 具有抵抗乙醇影响的药物或保健品组合物 | |
CN105125517A (zh) | 埃索美拉唑镁肠溶微丸胶囊及其制备方法 | |
CN105769813A (zh) | 一种适用于婴幼儿、老年患者的口服包衣细颗粒及其制备方法 | |
CN109908089A (zh) | 含nadh或nadph的纳米微球及其制备方法与应用 | |
CN105456223B (zh) | 美沙拉秦缓释微丸及其制备方法和美沙拉秦缓释胶囊 | |
WO2021184639A1 (zh) | 一种小儿消积止咳微囊制剂及其制备方法 | |
CN107811994B (zh) | 一种西里帕格pH依赖-时滞型结肠靶向微丸及其制备方法 | |
CN108042503A (zh) | 一种高效的炎琥宁肠溶片及制备方法 | |
CN103908441A (zh) | 一种Omega-3脂肪酸及其衍生物肠溶软胶囊及制备方法 | |
CN107982241A (zh) | 一种炎琥宁肠溶制剂及制备方法 | |
CN104906160B (zh) | 一种灯盏细辛提取物的肠溶制剂 | |
CN101874817B (zh) | 鸦胆子油肠溶微囊及其制备方法 | |
CN103845323B (zh) | 麦考酚酸及其盐肠溶制剂和制备方法 | |
CN101134037A (zh) | 利莫那班或其可药用盐的肠溶制剂及其制备方法 | |
TWI402084B (zh) | 微膠囊及其製造方法 | |
CN101879139A (zh) | 一种治疗消化性疾病的肠溶制剂及其制备方法 | |
CN112315991A (zh) | 一种血塞通药物组合物及其制备方法及应用 | |
CN102416007B (zh) | 一种盐酸二甲双胍肠溶胶囊 | |
CN103961308B (zh) | 一种布洛芬充气棉花糖的制备方法 | |
CN112999188A (zh) | 一种奥美拉唑肠溶微丸及其制备方法 | |
CN114762684B (zh) | 一种治疗帕金森的缓释胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 361027 Building 6, No. 2010 Wengjiao West Road, Haicang District, Xiamen City, Fujian Province Applicant after: XIAMEN LP PHARMACEUTICAL Co.,Ltd. Applicant after: Dynamic bio Pharmaceutical Technology (Xiamen) Co., Ltd. Address before: 361027, 4, 01, technical service center, 120 Xin Yuan Road, Xinyang street, Haicang District, Fujian, Xiamen, China Applicant before: XIAMEN LP PHARMACEUTICAL Co.,Ltd. Applicant before: Dynamic bio Pharmaceutical Technology (Xiamen) Co., Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Haijian Inventor after: Su Yijie Inventor after: Zhong Ming Inventor after: Su Bin Inventor before: Zhu Haijian Inventor before: Su Yijie Inventor before: Zhong Ming Inventor before: Su Bin Inventor before: Fang Changlin |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 361027 building 6, 2010 wengjiao West Road, Haicang District, Xiamen City, Fujian Province Patentee after: Lipin Pharmaceutical (Xiamen) Co.,Ltd. Patentee after: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. Address before: 361027 building 6, 2010 wengjiao West Road, Haicang District, Xiamen City, Fujian Province Patentee before: Lipin Pharmaceutical (Xiamen) Co.,Ltd. Patentee before: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 361026 building 6, 2010 wengjiao West Road, Haicang District, Xiamen City, Fujian Province Patentee after: Lipin Pharmaceutical (Xiamen) Co.,Ltd. Patentee after: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. Address before: 361027 building 6, 2010 wengjiao West Road, Haicang District, Xiamen City, Fujian Province Patentee before: Lipin Pharmaceutical (Xiamen) Co.,Ltd. Patentee before: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. |